Lineage Cell Therapeutics
LCTX
115 hedge funds and large institutions have $192M invested in Lineage Cell Therapeutics in 2021 Q3 according to their latest regulatory filings, with 15 funds opening new positions, 27 increasing their positions, 35 reducing their positions, and 14 closing their positions.
142% more call options, than puts
Call options by funds: $1.49M | Put options by funds: $617K
7% more first-time investments, than exits
New positions opened: 15 | Existing positions closed: 14
0.17% more ownership
Funds ownership: 45.12% → 45.28% (+0.17%)
0% more funds holding
Funds holding: 115 → 115 (0)
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
8% less capital invested
Capital invested by funds: $208M → $192M (-$16.6M)
23% less repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 35
Top Buyers
| 1 |
State Street
Boston,
Massachusetts
|
+$9.21M |
| 2 |
Wells Fargo
San Francisco,
California
|
+$1.78M |
| 3 |
JP Morgan Chase
New York
|
+$677K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$521K |
| 5 |
Rafferty Asset Management
New York
|
+$497K |
Top Sellers
| 1 |
Two Sigma Investments
New York
|
-$1.88M |
| 2 |
Two Sigma Advisers
New York
|
-$1.83M |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
-$1.13M |
| 4 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$945K |
| 5 |
DC
Defender Capital
Charlotte,
North Carolina
|
-$612K |
LCTX Hedge Fund Activity: Q3 2021 in Review
115 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q3 2021, worth a combined $192M — down 8% from $208M a quarter earlier.
Buyers outnumbered sellers: 15 funds opened new LCTX positions and 14 closed out — a net gain of 1 holder — while 27 added to existing stakes and 35 trimmed.
The largest buyer was State Street, adding an estimated $9.21M. The largest seller was Two Sigma Investments, cutting an estimated $1.88M.
- 115 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q3 2021, unchanged from Q2 2021.
- Funds reported $192M of Lineage Cell Therapeutics stock for Q3 2021, down 8% quarter-over-quarter.
- 15 funds opened new Lineage Cell Therapeutics positions in Q3 2021 and 14 closed out, a net change of +1 holder.
- The largest Lineage Cell Therapeutics buyer in Q3 2021 was State Street, an estimated $9.21M added.
- The largest Lineage Cell Therapeutics seller in Q3 2021 was Two Sigma Investments, an estimated $1.88M sold.
Based on aggregated 13F filings for Q3 2021.